Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

2021725 citationsJournal Articlebronze Open Access

Authors

Toni K. Choueiri · Dana-Farber Cancer Institute

Piotr Tomczak · Poznan University of Medical Sciences

Se Hoon Park · Samsung Medical Center

Balaji Venugopal · Beatson West of Scotland Cancer Centre

Thomas Ferguson · Provincial Polyclinical Hospital in Toruń

Yen‐Hwa Chang · Taipei Veterans General Hospital

Jaroslav Hájek

Abstract

Pembrolizumab treatment led to a significant improvement in disease-free survival as compared with placebo after surgery among patients with kidney cancer who were at high risk for recurrence. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).

Topics & Keywords

Renal cell carcinoma treatment Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 8, pp. 683-694

DOI: 10.1056/nejmoa2106391

Field-Weighted Citation Impact: 82.03